e-learning
resources
European Respiratory Review
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Bluthgen Maria-Virginia, Besse Benjamin
Source:
Eur Respir Rev 2015; 24: 582-593
Journal Issue:
December
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bluthgen Maria-Virginia, Besse Benjamin. Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. Eur Respir Rev 2015; 24: 582-593
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations
Source: Eur Respir J 2015; 46: 19-21
Year: 2015
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
Radiotherapy in the treatment of nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 207–243
Year: 2009
The treatment of stage IV non-small cell lung cancer with target therapies
Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC?
Year: 2013
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Biological therapies in nonsmall cell lung cancer
Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016
Year: 2017
Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 244–259
Year: 2009
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Second-line weekly docetaxel in advanced non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001
Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept